PEGylated insulin Lispro, (LY2605541)—a new basal insulin analogue
There is a clinical rationale for a basal insulin with a predictable action and low inter‐ and intra‐individual variability coupled with an improved side effect and metabolic profile. Since insulin therapy is anabolic and its initiation is commonly associated with weight gain, an insulin preparation associated with a beneficial weight profile would represent a particularly valuable therapeutic entity. LY2605541, or PEGylated insulin Lispro, has a large hydrodynamic size while still exerting the metabolic effects of insulin. This may reduce absorption and clearance of the compound following subcutaneous administration. ...
Source: Diabetes, Obesity and Metabolism - September 12, 2013 Category: Endocrinology Authors: T. M. Caparrotta, M. Evans Tags: REVIEW ARTICLE Source Type: research
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
This article is protected by copyright. All rights reserved.
PMID: 24026961 [PubMed - as supplied by publisher] (Source: Diabetes Metab)
Source: Diabetes Metab - September 11, 2013 Category: Endocrinology Authors: Owens DR, Matfin G, Monnier L Tags: Diabetes Metab Res Rev Source Type: research
Basal insulin analogues in the management of diabetes mellitus: What progress have we made?
This article is protected by copyright. All rights reserved. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - September 11, 2013 Category: Endocrinology Authors: David R. Owens, Glenn Matfin, Louis Monnier Tags: Review Article Source Type: research
Efficacy and safety of insulin lispro in geriatric patients with type 2 diabetes: a retrospective analysis of seven randomized controlled clinical trials.
CONCLUSION: Key measures of efficacy and safety in geriatric patients with T2DM were not significantly different from non-geriatric patients when utilizing insulin lispro. Insulin lispro may be considered a safe and efficacious therapeutic option for the management of T2DM in geriatric patients.
PMID: 23959960 [PubMed - as supplied by publisher] (Source: Aging Clinical and Experimental Research)
Source: Aging Clinical and Experimental Research - August 20, 2013 Category: Geriatrics Authors: Curtis BH, Rees TM, Gaskins KA, Sierra-Johnson J, Liu R, Jiang HH, Holcombe JH Tags: Aging Clin Exp Res Source Type: research
PEGylated Insulin Lispro, (LY2605541) – A new basal insulin analogue
Abstract
There is a clinical rationale for a basal insulin with a predictable action, low inter‐ and intra‐individual variability coupled with an improved side effect and metabolic profile. Since insulin therapy is anabolic and its initiation is commonly associated with weight gain, an insulin preparation associated with a beneficial weight profile would represent a particularly valuable therapeutic entity.
LY2605541, or PEGylated insulin Lispro, has a large hydrodynamic size while still exerting the metabolic effects of insulin. This may reduce absorption and clearance of the compound following subcutaneous administra...
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: Thomas Caparrotta, Marc Evans Tags: Unsolicited Review article Source Type: research
A randomized trial comparing the rate of hypoglycemia—assessed using continuous glucose monitoring—in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study)
ConclusionsWhile glargine noninferiority was not achieved, in young children with T1DM, there was a slight difference in hypoglycemia outcomes and glycemic control between glargine and NPH. Once‐daily glargine may therefore be a feasible alternative basal insulin in young populations, in whom administering injections can be problematic. (Source: Pediatric Diabetes)
Source: Pediatric Diabetes - June 1, 2013 Category: Endocrinology Authors: Thomas Danne, Areti Philotheou, David Goldman, Xiang Guo, Lin Ping, Anna Cali, Peter Johnston Tags: Original Article Source Type: research
Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: A review of the current evidence from clinical studies.
CONCLUSION: In patients with mild-to-moderate DKA, subcutaneous injections of insulin lispro every 1-2h offer a feasible alternative to continuous intravenous infusions of regular insulin, and should now be evaluated in larger, more appropriately powered studies.
PMID: 23642642 [PubMed - as supplied by publisher] (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 30, 2013 Category: Endocrinology Authors: Vincent M, Nobécourt E Tags: Diabetes Metab Source Type: research
The use of insulin analogues in pregnancy
Excellent glycaemic control is essential in pregnancy to optimise maternal and foetal outcomes. The aim of this review is to assess the efficacy and safety of insulin analogues in pregnancy. Insulin lispro and insulin aspart are safe in pregnancy and may improve post‐prandial glycaemic control in women with type 1 diabetes. However, a lack of data indicating improved foetal outcomes would suggest that there is no imperative to switch to a short‐acting analogue where the woman's diabetes is well controlled with human insulin. There are no reports of the use of insulin glulisine in pregnancy and so its use cannot be reco...
Source: Diabetes, Obesity and Metabolism - April 9, 2013 Category: Endocrinology Authors: K. Lambert, R. I. G. Holt Tags: REVIEW ARTICLE Source Type: research
Newer insulin analogs: advances in basal insulin replacement
Basal insulin analog therapy is the most common method of introducing insulin replacement therapy for the majority of patients with type 2 diabetes mellitus. Long‐acting insulin analogs provide relatively peakless and more physiologic insulin replacement therapy than neutral protaminated Hagedorn insulin. Recently 2 new basal insulin analogs have been developed with superior pharmacokinetic and pharmacodynamics properties; insulin degludec and a pegylated insulin lispro. These agents are generally well tolerated and have been evaluated in both type 1 and type 2 diabetes. In this article we review the results of clinical...
Source: Diabetes, Obesity and Metabolism - March 1, 2013 Category: Endocrinology Authors: Bernard Zinman Tags: REVIEW ARTICLE Source Type: research
Mylan, Biocon in deal on insulin products
Mylan and Biocon Ltd. are in a partnership to develop and commercialize three generic insulin analog products.
Financial terms of the profit-sharing deal weren't disclosed. But Mylan will be able to develop Glargine, the generic version of Sanofi's Lantus; Lispro, the generic version of Eli Lilly's Humalog; and Aspart, the generic version of Nov Nordisk's NovoLog. The rights are for the U.S., Canada, the European Union and elsewhere.
The worldwide sales of the three are $11.5 billion in 2012, Mylan… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 14, 2013 Category: Pharmaceuticals Source Type: research
Insulin neutral protamine lispro/insulin lispro: Type I IgE-mediated hypersensitivity in an elderly patient: case report
(Source: Reactions)
Source: Reactions - February 6, 2013 Category: Drugs & Pharmacology Tags: Short communication Source Type: research
